Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Background The prostate tumor microenvironment (TME) is immunosuppressive, with few effector T cells and enrichment of inhibitory immune populations, leading to limited responses to treatments such as immune checkpoint therapies (ICTs). The immune composition of the prostate TME differs across soft...

Full description

Bibliographic Details
Main Authors: Charles G Drake, Padmanee Sharma, Sumit K Subudhi, Patricia Troncoso, Sonali Jindal, Sreyashi Basu, Bilal A Siddiqui, Paul G Corn, Shalini S Yadav, Rebecca S S Tidwell, Christopher J Logothetis, Fei Duan, Brian F Chapin, Ai-Di Gu, Alexsandra B Espejo, Michelle Kinder, Curtis A Pettaway, John F Ward, Roland Knoblauch, Natalie Hutnick, Marco Gottardis
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/3/e006262.full

Internet

https://jitc.bmj.com/content/11/3/e006262.full

Similar Items